Keyphrases
Adult T-cell Leukemia
100%
Relapsed or Refractory
100%
Mogamulizumab
100%
C-X-C Chemokine Receptor Type 4 (CXCR4)
28%
Malignant Cells
28%
CD4+ T
14%
Monoclonal Antibody
14%
Malignancy
14%
Conventional Treatment
14%
Poor Prognosis
14%
Human T-cell Leukemia Virus Type 1 (HTLV-1)
14%
Phase I Clinical Trial
14%
Optimal Combination
14%
Phase II Clinical Trial
14%
Rash
14%
Novel Therapies
14%
Humanized
14%
Japan
14%
High Response Rate
14%
Conventional Chemotherapy
14%
Disease Control
14%
Area Cover
14%
Conventional Therapy
14%
Overall Response Rate
14%
Neutropenia
14%
Combination Chemotherapy
14%
Hematologic
14%
Aggressive Treatment
14%
Pyrexia
14%
Bridging Therapy
14%
Leukocytopenia
14%
Lymphocytopenia
14%
Allogeneic Hematopoietic Stem Cell Transplantation (allo-HSCT)
14%
Nonhematologic
14%
Peripheral T-cell Lymphoma
14%
Expert Commentary
14%
Aggressive Variant
14%
Multidrug Combination
14%
Infusion Reaction
14%
Hematological Adverse Events
14%
Medicine and Dentistry
Adult T-Cell Leukemia/Lymphoma
100%
Mogamulizumab
100%
Beta Chemokine
28%
Chemokine Receptor
28%
Adverse Event
14%
Clinical Trial
14%
Disease
14%
Monoclonal Antibody
14%
Cancer
14%
Infusion
14%
Fever
14%
Exanthem
14%
Combination Chemotherapy
14%
Leukopenia
14%
Human T-Lymphotropic Virus 1
14%
Lymphocytopenia
14%
Neutropenia
14%
Peripheral T-Cell Lymphoma
14%
Allogeneic Hematopoietic Stem Cell Transplantation
14%
Chemotherapy
14%
Pharmacology, Toxicology and Pharmaceutical Science
T Cell Leukemia
100%
Mogamulizumab
100%
Chemotherapy
28%
Chemokine Receptor
28%
Beta Chemokine
28%
Clinical Trial
14%
Adverse Event
14%
Disease
14%
Monoclonal Antibody
14%
Rash
14%
Neutropenia
14%
Leukopenia
14%
Fever
14%
Lymphocytopenia
14%
Human T-Lymphotropic Virus 1
14%
Peripheral T Cell Lymphoma
14%